Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nimenrix + Boostrix
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Nimenrix + Boostrix refers to the co-administration of two distinct vaccines developed by GSK: Nimenrix, a quadrivalent meningococcal conjugate vaccine, and Boostrix, a reduced-antigen content tetanus, diphtheria, and acellular pertussis (Tdap) vaccine. Nimenrix is designed to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135, and Y by inducing bactericidal antibodies against their capsular polysaccharides. Boostrix is indicated for booster immunization against tetanus, diphtheria, and pertussis. Clinical studies have demonstrated that the simultaneous administration of these two vaccines at separate injection sites is immunogenic and well-tolerated in adolescents, with no significant interference in the immune response to any of the component antigens. This combination is a standard component of adolescent immunization schedules in many regions.
- Other names
- meningococcal group A, C, W-135, and Y conjugate vaccine + tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccineMenACWY-TT + Tdap
02
Targets
BCR (Immunoglobulin G B Cell Receptor)CD4+ T-cell receptor (TCR) recognizing tetanus toxoid-derived peptidesFHA (Filamentous hemagglutinin)Neisseria meningitidis capsular polysaccharidePRN (Pertactin)TT (Tetanus toxoid)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)
Beyond the preview
Go deeper on Nimenrix + Boostrix.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nimenrix + Boostrix.